According to Johnson & Johnson, a listing of the emergency applications for the delivery of vaccines to low and middle income countries is critical under the COVAX program.
Johnson & Johnson announced Friday that it had provided the World Health Organization (WHO) with data on its COVID-19 vaccine emergency listing that would allow wider access to the one-dose shot.
J&J said emergency listing is a requirement for vaccine delivery to the COVAX (COVID-19 Vaccines Global Access Facility) program, which is jointly run by WHO and aims to deliver doses to low and middle income countries .
The J&J vaccine is given in a single dose and can be stored at normal refrigerator temperatures. This is a big selling point in countries with relatively weaker health infrastructure.
The vaccine is currently under review by the U.S. Health Department and a panel of experts from the U.S. Food and Drug Administration is expected to discuss approval for emergency use of the vaccine next week.
The vaccine is being introduced for the first time in South Africa outside of a large clinical trial.
J&J said last month that the vaccine was 66 percent effective against COVID-19 in a large global late-stage study against multiple variants of the coronavirus. The level of protection of the vaccine varied from 72 percent in the US to 66 percent in Latin America and 57 percent in South Africa.
The company said the data it submitted to WHO includes results from the late-stage study.
J & J signed an agreement in December to support the COVAX program.
The company and Gavi, the Vaccine Alliance, which also co-leads COVAX, anticipate they will close a pre-sale agreement that will deliver COVAX up to 500 million doses of the single-dose vaccine by 2022, J&J said.